Format

Send to

Choose Destination
Ann Pharm Fr. 2004 Nov;62(6):371-5.

[New fecal markers: recent developments and perspectives].

[Article in French]

Author information

1
Laboratoire de coprologie fonctionnelle, GH Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, F75652 Paris Cedex 13, France. nathalie.kapel@psl.ap-hop-paris.fr

Abstract

Fecal occult blood testing is the most widely prescribed screening test for colorectal cancer. Recent development of immunological tests has increased specificity. Fecal DNA analysis opens up a new field for early detection of this widespread neoplasia. Inflammatory bowel disease is another important area where the development of fecal markers provides an interesting alternative to the gold standard but costly and invasive endoscopic investigations with histological analysis of biopsy specimens. Fecal TNFalpha and calprotectin can now be proposed to distinguish organic from non-organic intestinal disease, so select candidates for further investigations, and to assess disease activity. Measurement of fecal elastase provides real progress in screening for exocrine pancreatic insufficiency in patients with malabsorption syndrome. The development of non-invasive fecal markers is thus of increasing interest, providing data about the entire gastrointestinal tract useful for screening and individual patient management.

PMID:
15550893
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center